1Inzucchi SE,Bergenstal RM,Buse JB,et al.Management of hyperglycemia in type 2 diabetes,2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care,2015,38(1):140-149.
2Bakris GL,Fonseca VA,Sharma K,et al.Renal sodiumglucose transport:role in diabetes mellitus and potential clinical implications[J].Kidney Int,2009,75(12):1272-1277.
3Ferrannini E,Solini A.SGLT2 inhibition in diabetes mellitus:rationale and clinical prospects[J].Nat Rev Endocrinol,2012,8(8):495-502.
4Vasilakou D,Karagiannis T,Athanasiadou E,et al.Sodiumglucose cotransporter 2 inhibitors for type 2 diabetes:a systematic review and metaanalysis[J].Ann Intern Med,2013,159(4):262-274.
5Kuo HW,Tiao MM,Ho SC,et al.Pioglitazone use and the risk of bladder cancer[J].Kaohsiung J Med Sci,2014,30(2):94-97.
6Wei L,Mac Donald TM,Mackenzie IS.Pioglitazone and bladder cancer:a propensity score matched cohort study[J].Br J Clin Pharmacol,2013,75(1):254-259.
7Diamant M,Nauck MA,Shaginian R,et al.Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes[J].Diabetes Care,2014,37(10):2763-2773.
